This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Jones Soda, FSI International: Early Volume Plays

Stocks in this article: JSDA FSII

NEW YORK ( TheStreet) -- Jones Soda (JSDA) was one of several stocks trading near $5 poised to move on above-average volume Thursday, as shares rallied more than 60% after announcing a distribution deal with the world's largest retailer.

Jones Soda announced a deal Thursday with Wal-Mart (WMT) that authorizes the soda maker to retail its products in Wal-Mart's approximately 3,800 U.S.-based stores. The deal increases Jones' total retail outlet distribution by nearly 10%, the company said.

Shares of Jones Soda jumped by 42 cents, or 61.8, to $1.10 in the premarket session. The 50-day average daily volume for Jones Soda is 496,000, according to the Nasdaq.

FSI International (FSII) jumped by 50 cents, or 18.2%, to $3.25 in the premarket session after the semiconductor equipment company raised its third-quarter revenue guidance to a range of $27 million to $29 million, from the prior range of $23 million to $25 million.

Assuming it can achieve anticipated gross profit margin and the operating expense levels, FSI International said it expects third-quarter net income of $5 million to $6 million, up from its prior guidance range of $2.5 million to $3 million. The 50-day average daily volume for FSI International is 577,000.

Elsewhere, Jamba (JMBA) slid by 14 cents, or 5.3%, to $2.50 in the premarket session after the company posted a first-quarter loss of 13 cents a share on revenue of $80.43 million, which came in below the two-analyst average estimate for a loss of 7 cents a share on revenue of $81.58 million. The 50-day average daily volume for Jamba is 1.39 million.

Alexza Pharmaceuticals (ALXA) climbed by 18 cents, or 6%, to $3.20 in the premarket session after the company said clinical study results show its Staccato Loxapine (AZ-004) reduced signs and symptoms of agitation as early as ten minutes after dosing in patients with schizophrenia or bipolar disorder.

In addition, Alexza Pharmaceuticals said that it has secured a $25 million committed equity financing facility with Azimuth Opportunity. The 50-day average daily volume for Alexza Pharmaceuticals is 165,000.

Beacon Power (BCON) rallied by 4 cents, or 11.1%, to 40 cents in the premarket session after Ardour Capital initiated coverage of the company with a buy rating and a $1.50 price target. The firm cited Beacon Power's significant growth prospects thanks to a future build out of its merchant frequency regulation plants. The 50-day average daily volume for Beacon Power is 1.08 million.

Sirius XM (SIRI) rebounded by 10 cents, or 12%, to 98 cents in the premarket session in the absence of any company-specific news. On Wednesday, Sirius XM shares fell more than 11% to 88 cents, the stock's second consecutive close below the $1 mark. The 50-day average daily volume for Sirius XM is 137 million.

More on Sirius XM
Sirius XM: 3 Biggest Risks

-- Written by Robert Holmes in Boston.

Check out all of Thursday's high-volume, under-$5 stocks at the Dollar Store. View the Dollar Store portfolio on StockPickr.

Follow Robert Holmes on Twitter and become a fan of on Facebook.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs